CAG
LGND icon

Crestwood Advisors Group’s Ligand Pharmaceuticals LGND Stock Holding History

Crestwood Advisors Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-88
Closed -$6K – 316
2017
Q1 		$6K Buy
+88
New +$5.79K ﹤0.01% 463

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Crestwood Advisors Group's LGND Position: Q2 2017 in Review

Crestwood Advisors Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 88 shares — an estimated $6K sold.

Crestwood Advisors Group first reported a position in LGND in Q1 2017 and held it in 1 quarter. The position peaked at $6K in Q1 2017. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Crestwood Advisors Group reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Crestwood Advisors Group sold 88 Ligand Pharmaceuticals shares in Q2 2017, an estimated $6K.
  • Crestwood Advisors Group first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Crestwood Advisors Group's Ligand Pharmaceuticals position peaked at $6K in Q1 2017.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.